Evidence map›Paper›PMID 20381876›Full record

ArticlePsychiatry research2010

Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.

Peter L Franzen, Daniel J Buysse, Mordechai Rabinovitz, Bruce G Pollock, Francis E Lotrich

Registry-linked trialAbstract read
In one paragraph

Article in Psychiatry research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07660107 (Clinical Trial of Oral Supplementation With Novel Mycolicibacterium), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07660107 nacompletednot on this mapstarted 2025, after this paper: background citation

Clinical Trial of Oral Supplementation With Novel Mycolicibacterium (KGA-10)

TypeinterventionalSponsorKioga Inc.Ran2025 to 2025Enrolled8ConditionsSafety, TolerabilityArmsHeat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly), Placebo (microcrystalline cellulose)
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Sleep disturbance and kynurenine metabolism in depression.Journal of psychosomatic research · 2017
    Article
  14. Article
  15. Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
  16. Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
  17. Article
  18. Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk.Prostaglandins, leukotrienes, and essential fatty acids · 2016
    Article
  19. Validation of the Behavioral Risk Factor Surveillance System Sleep Questions.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Peter L FranzenDepartment of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. franzenpl@upmc.edu
Daniel J Buysse
Mordechai Rabinovitz
Bruce G Pollock
Francis E Lotrich
University of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Pharmacogenomics of Interferon-Induced DepressionK23MH074012 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOTRICH, FRANCIS E · 2005 to 2009
$868k
The Impact of Sleep Deprivation on Affect Regulation in Young AdultsK01MH077106 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRANZEN, PETER L · 2007 to 2011
$721k
Geropsychopharmacology: Enhancing Benefit, Reducing RiskK24MH065416 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI POLLOCK, BRUCE G · 2002 to 2006
$616k
NCATS NIH HHS UL1 TR000005NIMH NIH HHS K01 MH077106NIMH NIH HHS K23 MH074012NIMH NIH HHS K24 MH065416NIMH NIH HHS MH65416NIMH NIH HHS MH74012NIMH NIH HHS MH77106
6 · The paper itself

Abstract

Major depressive disorder (MDD) often occurs during pegylated IFN-alpha2 (IFN-alpha) treatment. Identifying who is at risk for MDD in this population is essential, and epidemiological studies suggest that sleep may be related to depression risk. Controlling for pre-existing depression symptoms, we therefore examined whether sleep quality prior to IFN-alpha treatment would predict subsequent MDD incidence during IFN-alpha treatment. Adults with hepatitis C but without current clinical MDD (n=86) were evaluated prior to IFN-alpha treatment and then prospectively monitored during treatment using self-report measures of sleep quality (PSQI), depression (BDI), and anger and irritability (AIAQ), as well as with Structured Clinical Interviews for DSM-IV Axis I Disorders (SCID-I). During IFN-alpha treatment, 19% developed MDD, 19% developed subsyndromal depression with irritability, and one developed mania. Controlling for baseline depression symptoms and past history of depression, patients with worse sleep quality (PSQI > or = 10) prior to treatment had a significantly shorter time until they developed MDD or any severe psychiatric problem. These findings may have important implications for understanding, predicting, and possibly preventing depression, particularly in individuals treated with IFN-alpha.

Indexed as

AdultAnalysis of VarianceFemaleFollow-Up StudiesHealth SurveysHumansImmunologic FactorsInterferon-alphaIrritable MoodKaplan-Meier EstimateMajor Depressive DisorderMaleMiddle AgedProportional Hazards ModelsSleep Wake DisordersTime FactorsImmunologic FactorsInterferon-alpha

Identifiers

PMID20381876
PMCPMC2861158
OpenAlexW2056602748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.